January 11, 1999
AMERIPATH ACQUIRES PATHOLOGY PRACTICE

Riviera Beach, Florida, January 11, 1999 - AmeriPath, Inc.(Nasdaq: PATH) a physician practice management company focused on anatomic pathology services, continues to build on its regional business model by announcing the acquisition of Harper Pathology Group located in San Antonio, Texas. The practice had annual net revenues of $1.8 million in 1997. Terms of the transactions were not disclosed.

The Harper Pathology Group is AmeriPath's seventh acquisition in the state of Texas and second in the San Antonio area. The hospital-based practice employs three physicians who provide inpatient services at St. Luke's Baptist Hospital in San Antonio as well as operates an outpatient lab that serves the local physician community.

"This latest acquisition will help us to continue our leadership position, and regional business model in the state of Texas," said James C. New, President and CEO of AmeriPath, Inc. "Dr. Randall C. Harper's practice fits well with AmeriPath's Severance & Associates practice which was acquired in 1998, and allows for operational synergies and efficiencies in the future. We're proud to have Dr. Harper and his associates as a part of the AmeriPath team."

AmeriPath, Inc. is the nation's leading physician practice management company focused on providing anatomic pathology services to physicians, hospitals, national clinical laboratories and managed care organizations. The Company presently operates in ten states and employs 226 pathologists who provide medical services through outpatient pathology laboratories, hospital inpatient laboratories and outpatient surgery centers.

.........................................................................................................................

This release contains certain forward-looking statements regarding AmeriPath, including its operations and prospects. Past performance is not necessarily indicative of future results. In addition, AmeriPath's actual results could differ materially from the results anticipated in these forward-looking statements as a result of uncertainties, including risks relating to demand, pricing, government regulation, payments and reimbursement, changes on reimbursement coding guidelines, dependence upon contracts and pathologists, acquisitions, integration of acquired practices, the market for pathology services, competition, and other factors identified in AmeriPath's filings with the Securities and Exchange Commission.